Ad
related to: should i sell merck stock near me current
Search results
Results from the WOW.Com Content Network
On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...
There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates ...
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
The bad news: Its stock was down more than 10% in early trading, largely because of weaker-than-expected 2025 guidance. Merck reported $64.2 billion in sales for 2024, a 7% increase compared with ...
In terms of valuation, Merck stock is trading at a forward price-to-earnings (P/E) ratio of 14, which is near a peer-group average of 15 among pharmaceutical leaders like Johnson & Johnson, Pfizer ...
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...
Even beyond Keytruda, Davis has diversified Merck’s pipeline by tripling over the last three years the number of drug candidates in late-phase development, which represents over $50 billion in ...
Merck (MRK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ad
related to: should i sell merck stock near me current